Clinical Trial Technology

Incorporating technology to improve efficiency and success rate of clinical trials

Overview

The clinical trials stage is the longest step in the drug development process. Its success rate is estimated to be between 10% and 20%, depending on the therapeutic areas being considered. AI and telemedicine are being incorporated into clinical trials and are enabling virtual trials that are significantly cheaper to operate than traditional ones. Additionally, the automation of workflow processes and regulatory documentation requirements are reducing the operational costs of running a clinical trial. 

Technology has the potential to improve the success rates of clinical trials through data-driven feasibility studies and the crowdsourcing of clinical trial protocols, helping improve clinical trial designs and tackle the lack of commercial interest. As the pharmaceutical industry grapples with the pressure the drug development process puts on financial returns, clinical trial tech provides an avenue to expand returns by reducing the time and effort required to bring new drugs to market. 

Industry Updates

View all updatesicon
Market Sizing

The global Clinical Trial Tech market could reach USD 12.0 billion–16.8 billion by 2027

Conservative case

USD 0.0 Bn

Base case

USD 0.0 Bn

Expansion case

USD 0.0 Bn

Market Mapping


Growth-stage clinical trial management startups and incumbents most prominent

Startups in the growth-stage and providing clinical trial management solutions are most common, with several startups initially offering one specific solution before expanding into offering solutions across multiple parts of the clinical trial process.

Incumbents also focus on the clinical trial management segment in terms of partnerships and acquisitions, as these tend to have the most value in terms of improving the speed and cost of their own clinical trials.

The Disruptors


Disruptors partner with big pharma companies and clinical research organizations to provide services and technology

Clinical trial technology disruptors operate in partnership with their customers, which include big pharma and clinical research organizations that run and execute clinical trials. Whilst these customers have developed some technology solutions internally, they are always open for externally developed solutions that can provide efficiencies in terms of cost or time.

Funding History

Competitive Analysis


Filter by a segment or companies of your choice
expand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...

Incumbents


Pharmaceutical companies and clinical research organizations are increasingly adopting clinical trial technology to expedite the drug development process. Given that clinical trials are the most time-consuming step in drug development, any reduction in the time necessary for them would be a huge benefit. Patient recruitment is one of the major bottlenecks in clinical trials, as per incumbents such as AstraZeneca.  

Additionally, multiple tech companies have expressed interest and are working in the clinical trial tech space due to the significant volume of data that needs to be processed and the potential for providing cloud services and conducting Big Data analytics.

Recently, some incumbents have chosen to develop in-house solutions to address these issues, such as remote patient data collection to encourage trial participation and efficient clinical trial design. Other incumbents, however, prefer to work through partnerships with relevant startups, and, in some cases, with other incumbents that specialize in addressing challenges in the clinical trial process. Incumbent M&A activity in this space has been muted, with Oracle’s acquisition of clinical trial software provider goBalto in 2018 being the only notable deal.

In House Development
M&A
Partnership
Investment
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Notable Investors


?
Funding data are powered by Crunchbase
arrow
menuarrow
close

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo

The addressable market for Clinical Trial Tech globally is estimated at USD 30.0 billion

The total addressable market (TAM) refers to the total revenue opportunity available for a product or a service, while the actual market is the market size based on revenue projections.
We estimate a TAM of USD 30.0 billion globally. The clinical trial management segment is the largest (USD 12.4 billion), followed by virtual trials at (USD 7.2 billion). The addressable markets for site selection and startup (USD 4.2 billion) and patient and outcome data management (USD 3.4 billion) follow, with both processes critical to the overall success of a clinical trial. The market for patient recruitment (USD 1.9 billion) is limited in terms of monetization opportunities, in addition to being cannibalized by clinical trial management solutions that offer patient recruitment and retention modules.
See the Appendix for the breakdown and assumptions for TAM estimates.
The actual market for Clinical Trial Tech is estimated at USD 8.94 billion in 2022, with a penetration rate of 28.0%. This is expected to grow at a solid five-year compound annual growth rate (CAGR) of 12.4% to reach USD 15.0 billion in 2027, implying a penetration of 50.3%.

Summary

Our conservative case expects the market to grow at a much slower five-year CAGR of 9.6% to reach USD 13.2 billion by 2027. This assumes slower adoption of clinical trial technology due to market preferences and regulatory barriers, along with slower recovery in the volume of clinical trials. Our expansion case expects the market to grow at a five-year CAGR of 15.0% to reach USD 16.8 billion by 2027. This assumes faster adoption of technology in clinical trials, increased prevalence of virtual trials, and a quicker recovery in clinical trial volumes.

Appendix

The following factors were taken into account when estimating the TAM for the global Clinical Trial Tech market: 
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.